Otsuka submits NDA for centanafadine with US FDA to treat ADHD in children, adolescents and adults: Princeton, New Jersey Wednesday, November 26, 2025, 18:00 Hrs [IST] Otsuka Phar ...
More children and adults are being diagnosed with ADHD in some countries. Science is helping to understand why — and how best ...
Councillors have raised concerns over the 'scary' numbers of people waiting for mental health services in North Staffordshire ...
Professional women are swelling the ranks of mums giving birth to children with fetal alcohol spectrum disorder, a form of brain damage that affects thousands of New Zealanders. Yet FASD is being ...
Shahrzad Naso, 37, died in April 2024, leaving her blue-collar police officer husband Scott Naso devastated - but his ...
Medical staff have been questioned over delays to assessments of a 12-year-old boy who took his own life. Riley Townsend, ...
Japanese drugmaker Otsuka has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for ...
Inspectors have found "inconsistent experiences and outcomes" in how children with special educational needs and disabilities ...
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI). Clinical studies have shown that centanafadine significantly reduces core symptoms of ADHD in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback